Tag Archives: imperfect

Merck bags imperfect immunotherapy first with Keytruda cervical cancer approval

Merck & Co. is adding yet another immuno-oncology first under Keytruda’s belt. But the breadth of the win comes out less than ideal. The FDA has backed Keytruda’s use alongside chemotherapy, with or without Roche’s Avastin, for treating patients with persistent, recurrent or metastatic cervical cancer but only for those whose tumors express the PD-L1… Read More »